Press Releases

IR Mobile SiteTear sheetEmail pagePDF viewPrint viewRSS FeedsEmail AlertSocial Media Sharing


Year:
Notify me when new press releases are posted to this site.
Press Releases
11/21/2005FDA Accepts CUBICIN(R) sNDA and Grants Priority Review
10/27/2005Cubist Pharmaceuticals Introduces Lesson Plans for Science Teachers in Connection with New PBS Series
10/19/2005Cubist Pharmaceuticals Reports Record Third Quarter 2005 Results; Total Revenues $31.8 Million; Net Product Revenues $30.3 Million, up 18% over Q2; Loss Per Share Improves to 8 Cents
10/12/2005Cubist Pharmaceuticals to Announce Third Quarter 2005 Financial Results on Wednesday, October 19th, 2005; Conference Call to be Held 5:00 p.m. ET
9/26/2005Cubist Pharmaceuticals Files sNDA to Expand CUBICIN(R) Label for Staphylococcus Aureus Bacteremia With Known or Suspected Endocarditis; Company Requests Priority Review
9/09/2005CUBICIN(R) Phase 3 Endocarditis/Bacteremia Trial Abstract Accepted for ICAAC
9/01/2005Cubist Pharmaceuticals to Present at Upcoming Investor Conferences; Presentations at Thomas Weisel Partners Healthcare Tailwinds Conference 2005 and UBS 2005 Global Life Sciences Conference
8/10/2005Cubist Pharmaceuticals Announces the Appointment of Lindon M. Fellows as Senior Vice President, Technical Operations
8/09/2005Cubist Pharmaceuticals Announces the End of Patient Dosing in HepeX-B(TM) Hepatitis B Phase 2 Trial
7/20/2005Cubist Pharmaceuticals Reports Second Quarter 2005 Results; Total Revenues $28.3 Million; Net Product Revenues $25.6 Million, up 23% over Q1
7/06/2005Cubist Pharmaceuticals to Announce Second Quarter 2005 Financial Results on Wednesday, July 20th, 2005; Conference Call to be Held 5:00 p.m. EDT
6/27/2005CUBICIN Meets Primary Endpoints in Ground-Breaking Staphylococcus Aureus Endocarditis/Bacteremia Study; Cubist Plans to File sNDA for Expanded Label Before Year-end
6/09/2005CUBIST PHARMACEUTICALS ANNOUNCES SIGNIFICANT SALES MILESTONE
6/01/2005FRANCIS P. TALLY, M.D., CUBIST CHIEF SCIENTIFIC OFFICER, HONORED
5/23/2005CUBIST PHARMACEUTICALS TO PRESENT AT PACIFIC GROWTH EQUITIES CONFERENCE
5/16/2005CUBIST PHARMACEUTICALS APPOINTS DR. DAVID MANTUS AS HEAD OF REGULATORY
5/16/2005CUBIST PHARMACEUTICALS TO PRESENT AT NEEDHAM & COMPANY BIOTECHNOLOGY CONFERENCE
4/27/2005Cubist Pharmaceuticals to Present at Morgan Stanley Healthcare Conference
4/20/2005Cubist Pharmaceuticals Reports First Quarter 2005 Results; Reiterates 2005 Annual CUBICIN Revenue Guidance of $110-120 Million
4/04/2005Cubist Pharmaceuticals to Announce First Quarter 2005 Financial Results on Wednesday, April 20th, 2005
 
 Source: SNL Financial LC 
Rows 261 through 280 of 408 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Copyright 2013, © SNL Financial LC  Terms of Use